Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 39, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-07
DOI
10.1186/s13046-020-01694-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
- (2020) Margherita Passariello et al. Cancers
- Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
- (2020) Man Yee Keung et al. Journal of Clinical Medicine
- Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
- (2020) Barbara Schrörs et al. Frontiers in Oncology
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
- (2019) Raziye Piranlioglu et al. Nature Communications
- Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer
- (2019) Canan Kasikara et al. CANCER RESEARCH
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
- (2019) Javier Cortés et al. Future Oncology
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
- (2019) Wei Xiong Wen et al. PLoS One
- Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
- (2019) Gloria V. Echeverria et al. Science Translational Medicine
- Current Landscape of Immunotherapy in Breast Cancer
- (2019) Sylvia Adams et al. JAMA Oncology
- Advances in Targeted Therapies for Triple-Negative Breast Cancer
- (2019) Kelly E. McCann et al. DRUGS
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer
- (2019) Billy Samuel Hill et al. SEMINARS IN CANCER BIOLOGY
- Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion
- (2019) Crescenzo D’Alterio et al. SEMINARS IN CANCER BIOLOGY
- Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
- (2019) Margherita Passariello et al. Cancers
- Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
- (2019) Crescenzo D’Alterio et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
- (2019) Atsushi Tanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application
- (2019) Adachi et al. MOLECULES
- Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?
- (2019) Michelle Bauer et al. MOLECULES
- Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
- (2019) Margherita Passariello et al. Scientific Reports
- Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
- (2019) S. Napolitano et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
- (2019) Biancamaria Cembrola et al. Biomed Research International
- Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications
- (2018) Simona Camorani et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
- (2018) Emanuele Sasso et al. mAbs
- Aptamers: Promising Tools for Cancer Diagnosis and Therapy
- (2018) Laura Cerchia Cancers
- The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
- (2018) Chloé Grasselly et al. Frontiers in Immunology
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood–Brain Barrier
- (2017) Ilaria Monaco et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
- (2017) Carlos R. Gil Del Alcazar et al. Cancer Discovery
- Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers
- (2017) Simona Camorani et al. Scientific Reports
- Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer
- (2017) Simona Camorani et al. Theranostics
- Targeting Malignant Brain Tumors with Antibodies
- (2017) Rok Razpotnik et al. Frontiers in Immunology
- Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
- (2017) et al. Cancers
- Practical Approach to Triple-Negative Breast Cancer
- (2017) Vijayakrishna K. Gadi et al. Journal of Oncology Practice
- PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway
- (2016) Hong Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
- (2016) Elvira D'Ippolito et al. CANCER RESEARCH
- PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
- (2016) Adrian M. Seifert et al. CLINICAL CANCER RESEARCH
- Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
- (2016) George Plitas et al. IMMUNITY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Aptamers as targeted therapeutics: current potential and challenges
- (2016) Jiehua Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD
- (2016) Eliane Cortez et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells
- (2015) Simona Camorani et al. Oncotarget
- A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma
- (2015) Fengfei Wang et al. Oncotarget
- PDGFRB Promotes Liver Metastasis Formation of Mesenchymal-Like Colorectal Tumor Cells
- (2015) Ernst J.A. Steller et al. NEOPLASIA
- The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
- (2014) Lisa A. Newman et al. ANNALS OF SURGICAL ONCOLOGY
- PDGFR and Play Critical Roles in Mediating Foxq1-Driven Breast Cancer Stemness and Chemoresistance
- (2014) F. Meng et al. CANCER RESEARCH
- Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFRβ Aptamer
- (2014) Simona Camorani et al. MOLECULAR THERAPY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
- (2013) Giuseppe Curigliano et al. BREAST
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients
- (2013) David Akhavan et al. Cancer Discovery
- A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease
- (2012) Punit Kaur et al. BMC CANCER
- Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity
- (2012) Y. Kim et al. GENES & DEVELOPMENT
- PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer
- (2011) J. Liu et al. CLINICAL CANCER RESEARCH
- Aptamers as therapeutics
- (2010) Anthony D. Keefe et al. NATURE REVIEWS DRUG DISCOVERY
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations
- (2008) M. Cristofanilli et al. ANNALS OF ONCOLOGY
- Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target
- (2008) Sandra D Bohling et al. MODERN PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation